[1]王 艳,苏林冲,冉瑞金,等.艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎疗效及对患者血清微小RNA-141和微小RNA-335-5p表达的影响[J].陕西医学杂志,2024,(3):386-390.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.021]
　WANG Yan,SU Linchong,RAN Ruijin,et al.Efficacy of iguratimod combined with methotrexate in treatment of refractory rheumatoid arthritis and its effect on expressions of miR-141 and miR-335-5p[J].,2024,(3):386-390.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.021]
点击复制

艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎疗效及对患者血清微小RNA-141和微小RNA-335-5p表达的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
386-390
栏目:
药物与临床
出版日期:
2024-03-05

文章信息/Info

Title:
Efficacy of iguratimod combined with methotrexate in treatment of refractory rheumatoid arthritis and its effect on expressions of miR-141 and miR-335-5p
作者:
王 艳1; 2; 苏林冲3; 4; 冉瑞金5; 高圳昱3; 黄 侠3
(1.锦州医科大学,辽宁 锦州 121001; 2.湖北民族大学附属民大医院临床心理科,湖北 恩施 445000; 3.湖北民族大学附属民大医院风湿免疫科,湖北 恩施 445000; 4.风湿性疾病发生与干预湖北省重点实验室,湖北 恩施 445000; 5.湖北民族大学附属民大医院眼科,湖北 恩施 445000)
Author(s):
WANG Yan; SU Linchong; RAN Ruijin; GAO Zhenyu; HUANG Xia
(Jinzhou Medical University,Jinzhou 121001,China)
关键词:
难治性类风湿关节炎;  艾拉莫德;  甲氨蝶呤;  免疫功能;  微小RNA-141;  微小RNA-335-5p
Keywords:
Refractory rheumatoid arthritis;  Iguratimod;  Methotrexate;  Immune function;  miR-141;  miR-335-5p
分类号:
R 593.22
DOI:
DOI:10.3969/j.issn.1000-7377.2024.03.021
文献标志码:
A
摘要:
目的:观察艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎(RA)的疗效及对患者血清微小RNA-141(miR-141)和miR-335-5p表达的影响。方法:将难治性RA患者80例随机分为甲氨蝶呤组(单纯甲氨蝶呤治疗,40例)和联合艾拉莫德组(艾拉莫德联合甲氨蝶呤治疗,40例),均治疗3个月。比较两组临床疗效、免疫功能指标、骨代谢指标、炎症因子水平、症状改善情况以及miR-141和miR-335-5p表达水平。记录治疗期间不良反应发生情况。结果:联合艾拉莫德组总有效率高于甲氨蝶呤组(P<0.05)。两组血清免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、Ⅰ型胶原交联羧基末端肽(CTX-Ⅰ)、类风湿因子(RF)、分泌型糖蛋白-3α(Wnt-3α)、白细胞介素-1(IL-1)、IL-6、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、miR-141水平,以及28个关节疾病活动度(DAS28)评分、关节压痛指数、关节肿胀指数较治疗前降低,且联合艾拉莫德组低于甲氨蝶呤组(均P<0.05)。血清miR-335-5p、骨碱性磷酸酶(B-ALP)水平较治疗前升高,且联合艾拉莫德组高于甲氨蝶呤组(均P<0.05)。晨僵时间较治疗前缩短,且联合艾拉莫德组短于甲氨蝶呤组(均P<0.05)。治疗期间,联合艾拉莫德组与甲氨蝶呤组总不良反应发生率比较差异无统计学意义(P>0.05)。结论:相较于单纯甲氨蝶呤治疗,艾拉莫德联合甲氨蝶呤可进一步改善难治性RA患者免疫功能,改善相关细胞因子水平及炎症反应,缓解患者症状,同时具有良好安全性。艾拉莫德的治疗作用可能与调控血清miR-141、miR-335-5p水平有关。
Abstract:
Objective:To observe the efficacy of iguratimod combined with methotrexate in the treatment of refractory rheumatoid arthritis(RA)and its effect on the expressions of microRNA-141(miR-141)and miR-335-5p.Methods:A total of 80 patients with refractory RA were randomly divided into methotrexate group(treated with MTX alone,40 cases)and combined iguratimod group(treated with iguratimod combined with MTX,40 cases).All patients were treated for 3 months.The clinical efficacy,immune function indexes,bone metabolism indexes,inflammatory factor levels,symptom improvement,and expression levels of miR-141 and miR-335-5p were compared between the two groups.The occurrence of adverse reactions during the treatment was recorded.Results:The combined iguratimod group had a significantly higher overall response rate than the methotrexate group(P<0.05).The serum levels of IgG,IgA,IgM,CTX-Ⅰ,RF,Wnt-3α,IL-1,IL-6,CRP,TNF-α,miR-141,and DAS28 score,joint tenderness index and joint swelling index in two groups were lower than those before treatment,and those in combined iguratimod group were lower than those in methotrexate group(all P<0.05).The levels of serum miR-335-5p and B-ALP were higher than those before treatment,and those in combined iguratimod group were higher than those in methotrexate group(all P<0.05).The duration of morning stiffness in combined iguratimod group was shorter than that in methotrexate group(all P<0.05).During the treatment,there was no significant difference in total incidence of adverse reactions between two groups(P>0.05).Conclusion:Compared with methotrexate alone,iguratimod combined with methotrexate can further improve the immune function of patients with refractory RA,improve the levels of related cytokines and inflammatory response,relieve the symptoms of patients,and has a good safety profile.The therapeutic effect of iguratimod may be related to the regulation of serum miR-141 and miR-335-5p levels.

参考文献/References:

[1] ALSHARARI D M,OBEIDAT L A,KHASAWNEH H K,et al.Rheumatoid arthritis interstitial lung disease:Measuring and predictive factors among patients treated in rehabilitation clinics at royal medical services[J].Med Arch,2020,74(6):450-454.
[2] 吕媛,陈向红,黄闰月,等.化瘀强肾通痹方联合甲氨蝶呤治疗类风湿关节炎的临床观察[J].中国中西医结合杂志,2019,39(5):547-552.
[3] 吴佳,梁翼,李敏,等.艾拉莫德联合甲氨蝶呤、雷公藤多苷对类风湿关节炎关节软骨细胞损伤的修复作用及安全性分析[J].安徽医药,2022,26(1):183-187.
[4] 邓丽,文振华,田锋,等.艾拉莫德通过TLR4/NF-κB通路抑制骨关节炎软骨细胞模型凋亡及炎症反应[J].国际检验医学杂志,2023,44(3):316-321.
[5] 中华医学会风湿病学分会.类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志,2010,5(4):265-270.
[6] ALETAHA D,NEOGI T,SILMAN A J,et al.The 2010 rheumatoid arthritis classification criteria:An american college of rheumatology/european league against rheumatism collaborative initiative[J].Arthritis Rheum,2010,62(9):2569-2581.
[7] 孙张弛,杨君,张小芳,等.维生素D联合美洛昔康治疗类风湿关节炎效果及对炎症指标的影响观察[J].中国药师,2021,24(12):2204-2208.
[8] 曾翠青,谈平,张洞于,等.桂枝附子汤加味联合西药治疗类风湿关节炎继发骨质疏松临床观察[J].中华中医药学刊,2019,37(11):2737-2740.
[9] BAKER N A,CARANDANG K,DODGE C,et al.Occupational therapy is a vital member of the interprofessional team-based approach for the management of rheumatoid arthritis:Applying the 2022 american college of rheumatology guideline for exercise,rehabilitation,diet,and additional integrative interventions for rheumatoid arthritis[J].Arthritis Care Res(Hoboken),2023,75(8):1618-1624.
[10] 何娅娜,陈新宇,罗云涛,等.加味桂枝附子汤联合艾灸治疗类风湿关节炎疗效研究[J].陕西中医,2023,44(11):1562-1565.
[11] PHUKAN P,BARMAN B,CHENGAPPA N K,et al.Diffusion tensor imaging analysis of rheumatoid arthritis patients with neuropsychiatric features to determine the alteration of white matter integrity due to vascular events[J].Clin Rheumatol,2022,41(10):3169-3177.
[12] CONSTIEN D,DAVIDSON E,PHILLIPS L R.Patient perspectives on the 2022 american college of rheumatology guideline for exercise,rehabilitation,diet,and additional integrative interventions for rheumatoid arthritis[J].Arthritis Care Res(Hoboken),2023,75(8):1616-1617.
[13] 王凛介,李永红,孙建,等.甲氨蝶呤对类风湿关节炎患者骨破坏抑制及血清IL-1β和TNF-α的影响[J].河北医药,2019,41(1):58-61.
[14] 毛小红,方洁.艾拉莫德联合常规治疗对不同IgG滴度类风湿关节炎患者疗效与安全性的回顾性分析[J].中国药师,2020,23(6):1127-1129.
[15] 张学平,金钰,邵宏伟,等.血清lncRNA MEG3、miR-141表达对类风湿性关节炎诊断价值分析[J].疑难病杂志,2021,20(1):72-76.
[16] 施卫民,刘棒,王文琴.艾拉莫德联合改善病情的抗风湿药治疗类风湿关节炎合并骨质疏松的疗效分析[J].临床药物治疗杂志,2023,21(2):31-35.
[17] 刘颖,林书典,潘楚瑛,等.艾拉莫德对类风湿关节炎患者免疫功能及血清RF抗-CCP及Wnt-3α的影响[J].河北医学,2021,27(5):732-737.
[18] 陈士军,朱卫民,田培军.小剂量雷公藤总苷联合甲氨蝶呤对类风湿关节炎患者临床症状、炎性因子及关节功能的影响[J].临床误诊误治,2020,33(3):52-56.
[19] 冯佳,龚书识,夏燕,等.艾拉莫德对类风湿关节炎外周血破骨细胞分化及破骨细胞相关基因表达的影响[J].中国骨质疏松杂志,2019,25(1):97-102.
[20] 伦晓名,沈育娟,邢倩,等.艾拉莫德治疗类风湿关节炎的临床疗效及对血清学指标的影响[J].医学综述,2020,26(14):2886-2890.
[21] 吴系美,李博,佘若男,等.来氟米特与艾拉莫德联合治疗老年活动性类风湿关节炎患者的价值分析[J].中国病案,2021,22(4):99-102.
[22] 李良,孙银娣,李亚峰,等.四妙二藤汤联合双氯芬酸钠对类风湿关节炎患者关节情况、炎症指标和复发率的影响[J].陕西中医,2019,40(10):1397-1399.
[23] 马侗,张哲,王冬梅,等.雷公藤多苷联合艾拉莫德治疗RA合并间质性肺病的疗效及对血清HIF-1α、IL-22水平的影响[J].广西医科大学学报,2019,36(1):45-48.
[24] 袁芳芳,陈亚慧,林吉霞,等.艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎疗效及对患者血清SOD、CTX-Ⅰ水平影响[J].药物流行病学杂志,2020,29(3):163-165.
[25] 刘昌莲,贺冬冬,李晓明,等.艾拉莫德治疗类风湿关节炎疗效及对患者免疫炎症因子水平和骨代谢指标的影响[J].陕西医学杂志,2020,49(5):603-607.
[26] 张晓华,王利,刘丹,等.艾拉莫德治疗活动性类风湿关节炎合并骨量低下疗效及对患者骨代谢及外周血免疫指标的影响研究[J].陕西医学杂志,2021,50(4):482-484.

相似文献/References:

[1]刘昌莲,贺冬冬,李晓明,等.艾拉莫德治疗类风湿关节炎疗效及对患者免疫炎症因子水平和骨代谢指标的影响*[J].陕西医学杂志,2020,49(5):603.
　LIU Changlian,HE Dongdong,LI Xiaoming,et al.Clinical efficacy of Iguratimod in the treatment of rheumatoid arthritis and its effect on the levels of immune inflammatory factors and the indexes of bone metabolism[J].,2020,49(3):603.
[2]张晓华,王 利,刘 丹,等.艾拉莫德治疗活动性类风湿关节炎合并骨量低下疗效及对患者骨代谢及外周血免疫指标的影响研究[J].陕西医学杂志,2021,50(4):482.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.026]

备注/Memo

备注/Memo:
基金项目:湖北省卫生健康委员会青年人才项目(WJ2019Q024)
更新日期/Last Update: 2024-03-05